Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and their Combination in Patients with Chronic Kidney Disease: A Randomized Cross-Over Clinical Trial

Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage

(2021) Peter Kolkhof et al.   AMERICAN JOURNAL OF NEPHROLOGY

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

(2021) Bertram Pitt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial

(2021) Rajiv Agarwal et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

(2021) Niels Jongs et al.   Lancet Diabetes & Endocrinology

The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists

(2021) Michele Provenzano et al.   Kidney International Reports

Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy

(2021) Peter Rossing et al.   Kidney International Reports

Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial

(2020) Megumi Oshima et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Dapagliflozin in Patients with Chronic Kidney Disease

(2020) Hiddo J.L. Heerspink et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

(2020) George L. Bakris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.

(2020) Megumi Oshima et al.   KIDNEY INTERNATIONAL

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

(2019) Vlado Perkovic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial

(2019) Carol Pollock et al.   Lancet Diabetes & Endocrinology

Regulation of Potassium Homeostasis

(2014) B. F. Palmer   Clinical Journal of the American Society of Nephrology

Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial

(2014) Katsuyuki Ando et al.   Lancet Diabetes & Endocrinology

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

(2013) H. J. Lambers Heerspink et al.   DIABETES OBESITY & METABOLISM

An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function

(2011) Frank A. Holtkamp et al.   KIDNEY INTERNATIONAL

Mechanisms in Hyperkalemic Renal Tubular Acidosis

(2009) F. E. Karet   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy

(2009) U. F. Mehdi et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY